DNA and RNA-based vaccines: principles, progress and prospects

被引:286
|
作者
Leitner, WW [1 ]
Ying, H [1 ]
Restifo, NP [1 ]
机构
[1] NCI, NIH, Bethesda, MD 20892 USA
关键词
genetic vaccines; dendritic cells; replicase;
D O I
10.1016/S0264-410X(99)00271-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
DNA vaccines were introduced less than a decade ago but have already been applied to a wide range of infectious and malignant diseases, Here we review the current understanding of the mechanisms underlying the activities of these new vaccines. We focus on recent strategies designed to enhance their function including the use of immunostimulatory (CpG) sequences, dendritic cells (DC), co-stimulatory molecules and cytokine- and chemokine-adjuvants. Although genetic vaccines have been significantly improved, they may not be sufficiently immunogenic for the therapeutic vaccination of patients with infectious diseases or cancer in clinical trials. One promising approach aimed at dramatically increasing the immunogenicity of genetic vaccines involves making them 'self-replicating'. This can be accomplished by using a gene encoding RNA replicase, a polyprotein derived from alphaviruses, such as Sindbis virus. Replicase-containing RNA vectors are significantly more immunogenic than conventional plasmids, immunizing mice at doses as low as 0.1 mu g of nucleic acid injected once intramuscularly. Cells transfected with 'self-replicating' vectors briefly produce large amounts of antigen before undergoing apoptotic death. This death is a likely result of requisite double-stranded (ds) RNA intermediates, which also have been shown to super-activate DC. Thus, the enhanced immunogenicity of 'self-replicating' genetic vaccines may be a result of the production of pro-inflammatory dsRNA, which mimics an RNA-virus infection of host cells. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:765 / 777
页数:13
相关论文
共 50 条
  • [21] Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy
    Jiang, L.
    Vader, P.
    Schiffelers, R. M.
    GENE THERAPY, 2017, 24 (03) : 157 - 166
  • [22] Multimeric RNAs for efficient RNA-based therapeutics and vaccines
    Kim, Dajeong
    Han, Sangwoo
    Ji, Yoonbin
    Moon, Sunghyun
    Nam, Hyangsu
    Lee, Jong Bum
    JOURNAL OF CONTROLLED RELEASE, 2022, 345 : 770 - 785
  • [23] RNA-based programmable DNA cleavage
    King, Madeleine B.
    Lapinaite, Audrone
    NATURE CHEMICAL BIOLOGY, 2024, 20 (06) : 664 - 665
  • [24] Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
    Aldosari, Basmah N.
    Alfagih, Iman M.
    Almurshedi, Alanood S.
    PHARMACEUTICS, 2021, 13 (02) : 1 - 29
  • [25] Prospects and progress of DNA vaccines for treating hepatitis B
    Chen, Margaret
    Jagya, Neetu
    Bansal, Ruchi
    Frelin, Lars
    Sallberg, Matti
    EXPERT REVIEW OF VACCINES, 2016, 15 (05) : 629 - 640
  • [26] Post RNA-based COVID vaccines myocarditis: Proposed mechanisms
    Kadkhoda, Kamran
    VACCINE, 2022, 40 (03) : 406 - 407
  • [27] Current Progress in Messenger RNA-Based Gene Therapy
    Lei, Sibei
    Zhang, Xueyan
    Li, Jingmei
    Gao, Yan
    Wu, Jieping
    Duan, Xingmei
    Men, Ke
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2020, 16 (07) : 1018 - 1044
  • [28] Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
    Larsen, Sasha E.
    Baldwin, Susan L.
    Coler, Rhea N.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 130 : S47 - S51
  • [29] Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
    Larsen, Sasha E.
    Baldwin, Susan L.
    Coler, Rhea N.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 130 : S47 - S51
  • [30] New Kids on the Block: RNA-Based Influenza Virus Vaccines
    Scorza, Francesco Berlanda
    Pardi, Norbert
    VACCINES, 2018, 6 (02)